Headquartered in Gaithersburg, MD Fiscal year ends December NYSE: EBS emergentbiosolutions.com
Emergent BioSolutions Inc. is a life sciences company focused on developing, manufacturing, and delivering medical countermeasures (MCMs) for biological and chemical threats, as well as naloxone products for opioid overdose emergencies. The company operates across two reportable segments: Commercial Products (NARCAN Nasal Spray and KLOXXADO Nasal Spray for opioid overdose) and MCM Products (anthrax vaccines and therapeutics including CYFENDUS, BioThrax, ANTHRASIL, and raxibacumab; smallpox/mpox products including ACAM2000, TEMBEXA, and CNJ-016 (VIGIV); botulism antitoxin BAT; and Ebola therapeutic Ebanga). The company also operates a bioservices business providing contract manufacturing for third parties. Emergent serves primarily the U.S. government through multi-year procurement contracts and is expanding internationally, with products approved in Saudi Arabia and Singapore. The company has over 25 years of experience in biodefense and maintains a diversified pipeline spanning smallpox, anthrax, botulism, Ebola, mpox, Japanese Encephalitis, and pandemic influenza preparedness. Updated
One of the key benefits of exchange traded funds (ETFs) is that they can offer immediate portfolio exposure to hundreds or even thousands of stocks. In that vein, two popular choices among…
Emergent BioSolutions Inc. is a life sciences company focused on developing, manufacturing, and delivering medical countermeasures (MCMs) for biological and chemical threats, as well as naloxone products for opioid overdose emergencies.
The Wall Street consensus 12-month price target for EBS is $11.00.
